ArticleEuropean journal of epidemiology2022
The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years.
Article in European journal of epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- The burden of COVID-19 based on disability-adjusted life years: a systematic review of available evidence.Frontiers in public health · 2025Pooled it
- Community-level COVID-19 vaccination promotion capacity and its association with vaccination dose per capita in China: an entropy-weighted TOPSIS and multilevel analysis.BMC public health · 2026Article
- Disentangling the force of infection of SARS-CoV-2 in Dutch long-term care facilities.BMC public health · 2025Article
- Calculation of COVID-19 disease burden using Monte Carlo simulation with dynamic disability weights and analysis of transmission characteristics.BMC public health · 2025Article
- The impact of COVID-19: consequences of a 3-Year struggle in Iran.BMC infectious diseases · 2025Article
- Article
- COVID-19 burden in Iran: disability-adjusted life years analysis from hospital data, 2020-2021.Archives of public health = Archives belges de sante publique · 2024Article
- Projecting COVID-19 intensive care admissions for policy advice, the Netherlands, February 2020 to January 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- The mortality burden related to COVID-19 in 2020 and 2021 - years of life lost and excess mortality in 13 countries and sub-national regions in Southern and Eastern Europe, and Central Asia.Frontiers in public health · 2024Article
- Disability-adjusted life years due to COVID-19 in Sri Lanka: a retrospective cross-sectional study.BMJ public health · 2023Article
- The daily updated Dutch national database on COVID-19 epidemiology, vaccination and sewage surveillance.Scientific data · 2023Article
- The burden of disease due to COVID-19 in Sweden 2020-2021: A disability-adjusted life years (DALYs) study.Scandinavian journal of public health · 2023Article
- Has COVID-19 increased inequality in mortality by income in the Netherlands?Journal of epidemiology and community health · 2023Article
- Burden of COVID-19 disease in Kurdistan province in west of Iran using disability-adjusted life years.Health science reports · 2023Article
- Article
- Estimating the disability adjusted life years associated with COVID-19 in Iran for the first 2 years of the pandemic.Frontiers in public health · 2023Article
- Direct impact of COVID-19 by estimating disability-adjusted life years at national level in France in 2020.PloS one · 2023Article
- Measuring disability-adjusted life years (DALYs) due to COVID-19 in Scotland, 2020.Archives of public health = Archives belges de sante publique · 2022Article
- Burden of disease of COVID-19 in the department of Nariño, Colombia, 2020-2021.Revista peruana de medicina experimental y salud publicaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
The impact of COVID-19 on population health is recognised as being substantial, yet few studies have attempted to quantify to what extent infection causes mild or moderate symptoms only, requires hospital and/or ICU admission, results in prolonged and chronic illness, or leads to premature death. We aimed to quantify the total disease burden of acute COVID-19 in the Netherlands in 2020 using the disability-adjusted life-years (DALY) measure, and to investigate how burden varies between age-groups and occupations. Using standard methods and diverse data sources (mandatory notifications, population-level seroprevalence, hospital and ICU admissions, registered COVID-19 deaths, and the literature), we estimated years of life lost (YLL), years lived with disability, DALY and DALY per 100,000 population due to COVID-19, excluding post-acute sequelae, stratified by 5-year age-group and occupation category. The total disease burden due to acute COVID-19 was 286,100 (95% CI: 281,700-290,500) DALY, and the per-capita burden was 1640 (95% CI: 1620-1670) DALY/100,000, of which 99.4% consisted of YLL. The per-capita burden increased steeply with age, starting from 60 to 64 years, with relatively little burden estimated for persons under 50 years old. SARS-CoV-2 infection and associated premature mortality was responsible for a considerable direct health burden in the Netherlands, despite extensive public health measures. DALY were much higher than for other high-burden infectious diseases, but lower than estimated for coronary heart disease. These findings are valuable for informing public health decision-makers regarding the expected COVID-19 health burden among population subgroups, and the possible gains from targeted preventative interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.